Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment ...
Researchers assessed the safety and efficacy of the novel PolaR-ICE regimen among patients with relapsed or refractory DLBCL in the second-line setting.
The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients. 2 ...
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...
A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.
The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR ...
Eptinezumab is associated with modest reductions in headache frequency for patients with chronic migraine who failed prior ...
Germ cell tumor (GCT) is one of the most common malignancies affecting young men. Approximately 30% of patients with metastatic disease experience disease progression following adequate first-line ...
The experimental drug erenumab (AMG 334, Amgen and Novartis) is effective and safe in patients with episodic migraine in whom previous treatments have failed, results of a new phase 3b trial have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results